Potential Deleterious Effects of Vasopressin in Chronic Kidney Disease and Particularly Autosomal Dominant Polycystic Kidney Disease

被引：28
作者：
Meijer, E. [1 ]
Boertien, W. E. [1 ]
Zietse, R. [2 ]
Gansevoort, R. T. [1 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands
[2] Erasmus MC, Dept Nephrol, Rotterdam, Netherlands
来源：
KIDNEY & BLOOD PRESSURE RESEARCH | 2011年 / 34卷 / 04期
关键词：
Vasopressin; Copeptin; Chronic kidney disease; Autosomal dominant polycystic kidney disease; Albuminuria; Proteinuria; Glomerular filtration rate; RENAL CONCENTRATING CAPACITY; GLOMERULAR-FILTRATION-RATE; RENIN-ANGIOTENSIN SYSTEM; RECEPTOR ANTAGONISTS; DIABETES-MELLITUS; ANTIDIURETIC ACTION; PLASMA VASOPRESSIN; SURROGATE MARKER; BRATTLEBORO RATS; SODIUM-EXCRETION;
D O I：
10.1159/000326902
中图分类号：
Q4 [生理学];
学科分类号：
071003 ;
摘要：
The antidiuretic hormone vasopressin is crucial for regulating free water clearance in normal physiology. However, it has also been hypothesized that vasopressin has deleterious effects on the kidney. Vasopressin is elevated in animals and patients with chronic kidney disease. Suppression of vasopressin activity reduces proteinuria, renal hypertrophy, glomerulosclerosis and tubulointerstitial fibrosis in animal models. The potential detrimental influence of vasopressin is probably mediated by its effects on mesangial cell proliferation, renin secretion, renal hemodynamics, and blood pressure. In this review, we discuss the increasing body of evidence pointing towards the contribution of vasopressin to chronic kidney disease progression in general and to autosomal dominant polycystic kidney disease in particular. These data allude to the possibility that interventions directed at lowering vasopressin activity, for example by the administration of vasopressin receptor antagonists or by drinking more water, may be beneficial in chronic kidney disease. Copyright (C) 2011 S. Karger AG, Basel
引用
收藏
页码：235 / 244
页数：10
相关论文
共 50 条
  • [31] Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease
    Boertien, Wendy E.
    Meijer, Esther
    Zittema, Debbie
    van Dijk, Marjan A.
    Rabelink, Ton J.
    Breuning, Martijn H.
    Struck, Joachim
    Bakker, Stephan J. L.
    Peters, Dorien J. M.
    de Jong, Paul E.
    Gansevoort, Ron T.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (11) : 4131 - 4137
  • [32] Pregnancy in Autosomal Dominant Polycystic Kidney Disease
    Al Sayyab, Mina
    Chapman, Arlene
    [J]. ADVANCES IN KIDNEY DISEASE AND HEALTH, 2023, 30 (05): : 454 - 460
  • [33] Autophagy and Autosomal Dominant Polycystic Kidney Disease
    Oto, Ozgur Akin
    Edelstein, Charles L.
    [J]. TURKISH JOURNAL OF NEPHROLOGY, 2023, 32 (01): : 8 - 15
  • [34] Hypertension in Autosomal Dominant Polycystic Kidney Disease
    Chapman, Arlene B.
    Stepniakowski, Konrad
    Rahbari-Oskoui, Frederic
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2010, 17 (02) : 153 - 163
  • [35] The pathogenesis of autosomal dominant polycystic kidney disease
    Sutters, Michael
    [J]. NEPHRON EXPERIMENTAL NEPHROLOGY, 2006, 103 (04): : E149 - E155
  • [36] Treatment of autosomal dominant polycystic kidney disease
    Torra, Roser
    [J]. MEDICINA CLINICA, 2014, 142 (02): : 73 - 79
  • [37] Autosomal dominant polycystic kidney disease and transplantation
    Niemczyk, Mariusz
    Niemczyk, Stanislaw
    Paczek, Leszek
    [J]. ANNALS OF TRANSPLANTATION, 2009, 14 (04) : 86 - 90
  • [38] Autosomal dominant polycystic kidney disease in children
    Cadnapaphornchai, Melissa A.
    [J]. CURRENT OPINION IN PEDIATRICS, 2015, 27 (02) : 193 - 200
  • [39] Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Edwards, Marie E.
    Chebib, Fouad T.
    Irazabal, Maria V.
    Ofstie, Troy G.
    Bungum, Lisa A.
    Metzger, Andrew J.
    Senum, Sarah R.
    Hogan, Marie C.
    El-Zoghby, Ziad M.
    Kline, Timothy L.
    Harris, Peter C.
    Czerwiec, Frank S.
    Torres, Vicente E.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (08): : 1153 - 1161
  • [40] Apelin is altered in subjects with autosomal dominant polycystic kidney disease and preserved kidney function
    Janssens, Peter
    Cools, Wilfried
    de Mota, Nadia
    Decuypere, Jean-Paul
    Torres, Vicente
    Wissing, Karl Martin
    Vennekens, Rudi
    Bammens, Bert
    Llorens-Cortes, Catherine
    Mekahli, Djalila
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (08) : 1907 - 1911
12345